What are the types of seizures and the recommended drug treatments with dosages for each type?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 14, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Types of Seizures and Drug Treatment with Dosages

Status Epilepticus (Convulsive)

For adults with convulsive status epilepticus, intramuscular midazolam, intravenous lorazepam, intravenous diazepam, and intravenous phenobarbital are established first-line treatments, with intramuscular midazolam superior when IV access is unavailable 1.

First-Line Treatment (Early Status Epilepticus)

  • Lorazepam IV: 0.1 mg/kg (typically 4 mg) - established efficacy in adults and children 1
  • Diazepam IV: 0.15-0.2 mg/kg (typically 10 mg) - established efficacy in adults and children 1
  • Midazolam IM: 10 mg (or 0.2 mg/kg) - superior to IV lorazepam when IV access unavailable in adults 1
  • Phenobarbital IV: 15 mg/kg - established efficacy in adults 1

Critical caveat: Respiratory depression occurs less frequently with benzodiazepines than with placebo, indicating untreated status epilepticus itself causes respiratory problems 1.

Second-Line Treatment (Established Status Epilepticus)

After benzodiazepine failure, valproate and levetiracetam represent safe and effective alternatives to phenobarbital and phenytoin 2. The 2024 ACEP guideline specifically addresses this scenario 3.

  • Levetiracetam IV: 60 mg/kg (maximum 4500 mg) - safer profile than traditional agents 2
  • Valproate IV: 40 mg/kg (maximum 3000 mg) - effective alternative 2
  • Fosphenytoin IV: 20 mg PE/kg - preferred over phenytoin for tolerability 1
  • Phenytoin IV: 20 mg/kg - acceptable alternative when fosphenytoin unavailable 1
  • Lacosamide IV: 200-400 mg - emerging option 4

Important warning: Second-line therapy is less effective than first-line (approximately 50% success vs 63-73%), and third-line therapy is substantially less effective 1.

Third-Line Treatment (Refractory Status Epilepticus)

For seizures persisting despite two adequate treatments, anesthetic agents are indicated 4:

  • Midazolam infusion: 0.2 mg/kg bolus, then 0.05-2 mg/kg/hr
  • Propofol infusion: 1-2 mg/kg bolus, then 2-10 mg/kg/hr
  • Phenobarbital: Additional loading doses of 5-10 mg/kg

Focal (Partial) Seizures - Treatment-Resistant Epilepsy

Pregabalin, perampanel, and vigabatrin are established as effective for reducing seizure frequency in treatment-resistant adult focal epilepsy 5.

Established Efficacy (Level A)

  • Pregabalin: 150-600 mg/day divided BID-TID 5
  • Perampanel: 4-12 mg once daily 5
  • Vigabatrin: 1000-3000 mg/day (not first-line due to visual field defects) 5

Should Be Considered (Level B)

  • Lacosamide: 200-400 mg/day divided BID 5
  • Eslicarbazepine: 800-1200 mg once daily 5
  • Oxcarbazepine: 600-2400 mg/day divided BID (particularly for children 1 month-4 years) 5
  • Zonisamide: 300-500 mg/day for children 6-17 years 5

First-Line Monotherapy Options

  • Carbamazepine: 400-1600 mg/day divided BID-TID (adults) 6
  • Lamotrigine: 100-400 mg/day (adults and elderly) 6
  • Oxcarbazepine: 600-2400 mg/day (children) 6

Generalized Seizures

Generalized Tonic-Clonic Seizures

Valproate is supported by pragmatic trials for generalized seizures, except in women of childbearing age where individualized risk-benefit assessment is mandatory 6.

  • Valproate: 15-60 mg/kg/day divided BID-TID (avoid in women of childbearing potential) 6
  • Lamotrigine: 100-400 mg/day (immediate or extended-release) - established for treatment-resistant GTC 5
  • Levetiracetam: 1000-3000 mg/day divided BID - should be considered for treatment-resistant GTC 5

Juvenile Myoclonic Epilepsy

  • Levetiracetam: 1000-3000 mg/day divided BID - should be considered 5
  • Valproate: 15-60 mg/kg/day (first-line but avoid in women of childbearing age) 6

Lennox-Gastaut Syndrome

Rufinamide is established as effective add-on therapy for Lennox-Gastaut syndrome 5.

  • Rufinamide: 45 mg/kg/day or 3200 mg/day (whichever is less) divided BID 5
  • Clobazam: 0.25-0.5 mg/kg/day (maximum 40 mg/day) - should be considered as add-on 5

Infantile Spasms (West Syndrome)

Vigabatrin is unanimously recommended as first-line treatment for infantile spasms, particularly in tuberous sclerosis 7.

  • Vigabatrin: 50-150 mg/kg/day divided BID 7

Non-Convulsive Status Epilepticus

Treatment follows similar principles to convulsive status epilepticus but with modified approach 4:

  • First-line: Benzodiazepines (lorazepam, midazolam)
  • Second-line: Fosphenytoin, valproate, levetiracetam, lacosamide, phenobarbital - with slower administration rates and dosage modulation 4
  • Alternative oral therapy: Carbamazepine, phenytoin, perampanel, zonisamide, topiramate, pregabalin, phenobarbital 4

Critical distinction: General anesthesia is not indicated for continuous partial epilepsy, and for "complex partial" status epilepticus, exhaust multiple ASMs before considering anesthesia 4.

Special Populations

Children with Treatment-Resistant Focal Epilepsy

  • Levetiracetam: 20-60 mg/kg/day divided BID (ages 1 month-16 years) 5
  • Oxcarbazepine: 8-46 mg/kg/day divided BID (ages 1 month-4 years) 5
  • Zonisamide: 5-8 mg/kg/day (ages 6-17 years) 5

Elderly Patients

  • Lamotrigine: 100-200 mg/day (start low, titrate slowly) 6
  • Gabapentin: 900-1800 mg/day divided TID 6

Key principle: Use the lowest effective maintenance dose based on efficacy and tolerability, with careful attention to the epilepsy syndrome and patient-specific factors 6.

References

6
Research

Treating epilepsy across its different stages.

Therapeutic advances in neurological disorders, 2010

7
Research

Overview of therapeutic options for epilepsy.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2022

Related Questions

Is it safe for a patient to drive when a suspected seizure has not been confirmed?
What is the appropriate initial management for a patient presenting with a first-time seizure?
How should a 10‑minute witnessed seizure with upper‑extremity jerking, altered consciousness, and post‑ictal crying be managed?
After stabilizing the infant following oxygenation, which secondary assessment steps should be performed, including chest X‑ray, evaluation for reversible causes of seizure, and electroencephalogram?
What is the definition of a seizure?
What is the extent of systemic absorption of timolol ophthalmic drops?
In organophosphate poisoning, after administering atropine, the patient has pupillary dilation and calf muscle fasciculations; how should the treatment be adjusted?
Is a lump in the skin considered a cutaneous lesion?
Does the vitamin D (25‑hydroxyvitamin D) blood test require fasting?
In an adult patient with major depressive disorder and no known contraindications, should escitalopram or vortioxetine be used as first‑line treatment, and what factors guide the choice or switching between them?
How can an adult be diagnosed with celiac disease without a duodenal biopsy, and what criteria must be met?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.